Please login to the form below

Not currently logged in
Email:
Password:

Hetlioz

This page shows the latest Hetlioz news and features for those working in and with pharma, biotech and healthcare.

BMS' Opdivo backed as melanoma therapy in EU

BMS' Opdivo backed as melanoma therapy in EU

Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally blind adults - which was approved in the US last year -

Latest news

  • FDA approves sleep disorder drug for blind people FDA approves sleep disorder drug for blind people

    Vanda Pharmaceuticals wins backing for Hetlioz to improve a person’s body clock. ... This means Vanda was able to take advantage of a number of development incentives due to the orphan-drug designation for Hetlioz.

  • FDA panel backs sleep pattern drug for blind FDA panel backs sleep pattern drug for blind

    Vanda’s Hetlioz intended to improve circadian rhythms in people who cannot see. ... A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics